DBD Search
Grant R. Zimmermann
Managing Director of Business Development, Blavatnik Biomedical Accelerator
Displaying: 41 - 50 of 67 Results
Invention
Migration inhibitory factor (MIF) knockout mouse
To study the biological role of migration inhibitory factor (MIF), a pleiotropic cytokine, we generated a mouse strain lacking MIF by gene targeting in embryonic stem cells. Analysis of the role of MIF during sepsis showed that MIF-/- mice were…
Investigators
- John R. David
- Marcelo Torres Bozza
- Craig Gerard
Invention
Targeted inhibition of the SREBP-mediator interaction as a novel therapeutic
While most therapeutic approaches aimed at altering gene expression programs target upstream signaling pathways or nuclear translocation checkpoints, Scientists at the Wagner lab have provided mechanistic insights supporting an alternative approach,…
Investigators
- Gerhard Wagner
- Anders M. Naar
- Haribabu Arthanari
Invention
Mass spectrometry-based in vitro kinome activity assay
This technology is a new generation, high-throughput assay to quantitatively assess the activity of the kinome in a variety of samples. Cocktails of synthetic peptides are combined with a sample of interest and phosphorylated by kinases in the…
Investigators
- Steven P. Gygi
- Judit Villen
- Kazuishi Kubota
- Yong Yu
Invention
Inhibitors of protein-processivity factor
Harvard investigators have discovered that Pol interacts with a processivity factor at a site that is distinct from sites of normal interaction between known Pol family members and other cellular factors. Unlike most protein-protein interactions,…
Investigators
- Donald M. Coen
- James M. Hogle
- Harmon Zuccola
- Kristie Grove Bridges
- Carl Elkin
- Scott R. Lokey
Invention
A fusion intermediate state of HIV-1 gp41, targeted by broadly neutralizing antibodies, for purposes of vaccination
HIV infection generally induces a strong antibody response to the envelope glycoprotein, the sole antigen on the virion surface. Most of the induced antibodies are ineffective in preventing infection, however, as they are either non-neutralizing or…
Investigators
- Stephen C. Harrison
- Gary H. Frey
- Bing Chen
Invention
Method for producing site-specific recombination of DNA in a transgenic non-human mammal at chromosomal regions containing Flp-recognition sites
A method is disclosed for producing site-specific recombination of DNA in a transgenic non-human mammal at chromosomal regions containing Flp-recognition sites (e.g., a DNA sequence containing an FRT site). The invention in particular discloses the…
Investigators
- Susan M. Dymecki
- A. Francis Stewart
Invention
Metabolic labeling and direct imaging of choline-containing phospholipids in vivo
A functional analog of a metabolic phospholipid precursor has been devised that, when contacted with cells, becomes incorporated into a cells endogenous phospholipids through cellular metabolic processes. The resulting phospholipids contain a moiety…
Investigators
- Adrian Salic
Invention
anti-MARCO monoclonal antibody
The monoclonal antibody recognizes the Macrophage Receptor with Collagenous structure (MARCO). The scavenger receptors (SRs) expressed by macrophages are thought to play an important role in the immune response against bacteria by mediating binding…
Investigators
- Lester Kobzik
- Aiyappa M. Palecanda
Research Tool
Crx Knock Out Mice
Homozygotes are viable and fertile and do not display any gross physical abnormalities. These mice do not elaborate photoreceptor outer segments and synaptic termini, and they lack cone and rod activities as assayed by electroretinograms. Circadian…
Investigators
- Connie Cepko
Research Tool
ACTB:FLPe B6N Transgenic Mice
This transgenic strain expresses a variant of the Saccharomyces cerevisiae FLP1 recombinase gene under the direction of the human ACTB promoter. The FLPe recombinase variant exhibits enhanced thermostability with recombination activity being…
Investigators
- Susan M. Dymecki